Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery

Stopped early · Phase 2 · Has a placebo group

Conditions studied: CABG

In brief

This research is being done to see if giving a hormone called GLP-1 can improve heart function and reduce length of stay in the Cardiac Surgical Intensive Care Unit (CSICU) in people who have non-emergent coronary artery bypass graft (CABG) surgery.

Key facts

Study ID

NCT00966654

Run by

Johns Hopkins University

People needed

12

Starts

2008-09-01

Expected to finish

2012-09-01

Last updated by the study team

2017-07-12

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and Females age > 18 years of age
• Able to consent
• Scheduled for non-emergent coronary artery bypass graft (CABG)
• Have an ejection fraction < 35%
• Ischemic patients with Left Ventricular Dysfunction (LVD) who need a valve procedure with their CABG

You may not qualify if…

• Emergency coronary artery bypass graft surgery
• Patients with an ejection fraction > 35%
• Repeat or redo CABG patients
• Patients with a history of pancreatitis
• Pregnant or lactating females

Where it is running

• Johns Hopkins Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.